MedPath

The Efficacy of Amino Acid Supplementation in Treating Environmental Enteric Dysfunction Among Children At Risk of Malnutrition

Not Applicable
Not yet recruiting
Conditions
Amino Acid, Stunting, Environmental Enteric Dysfunction
Registration Number
NCT06617130
Lead Sponsor
Kamuzu University of Health Sciences
Brief Summary

A randomised controlled open label clinical trial to determine whether addition of indispensable amino acids (IAA) to standard complementary food will reduce occurrence of Environmental Enteric Dysfunction (EED) compared with provision of standard complementary food without IAA in healthy Malawian children aged 18-36 months with or without stunting.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
66
Inclusion Criteria
  • All children identified from the Mangochi DSS whose guardian/parent desires screening will be eligible for screening. This will first include age, weight, length, and MUAC assessment. If a participant meets age and anthropometric criteria, they will be invited to undergo full inclusion/exclusion criteria assessment, consent, and randomization.

In order to be eligible to participate in the study, an individual must meet all of the following criteria:

  1. 18-36 months old (now agreed to by all countries)
  2. Stunted (LAZ<-2)
  3. Of either sex
  4. Able and willing to undergo HIV testing
  5. Parent, carer, or guardian able and willing to give written, informed consent
  6. A positive HIV test result will not be an exclusion criterion.
Exclusion Criteria
  • An individual who meets any of the following criteria will be excluded from participation in this study:

    1. Under 18 months of age
    2. Over 36 months old
    3. Wasted (weight-for-length Z-score less than -2)
    4. Overweight (weight-for-length Z-score greater than 2)
    5. Have had diarrhea (by self-report) in the preceding month
    6. Sibling or twin of another participating study child (2 children of different families in the same household are both eligible)
    7. Have any underlying condition other than HIV, which in the opinion of the investigator would put the subject at undue risk of failing study completion or would interfere with analysis of study results

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
corn soy bean flour porridge with added indespensable amino acids30 days

Primary Efficacy Endpoint:

We hypothesize that adding 12mg IAA to corn-soy blended flour porridge provided to Malawian children aged 18-36 months with or without stunting will reduce gut permeability as measured by the Lactulose:Rhamonse ratio test when provided over 30 days compared to corn-soy blended flour porridge without added IAA.

Secondary Outcome Measures
NameTimeMethod
Corn soy bean flour porridge30 days

We hypothesize that adding 12mg IAA to corn-soy blended flour porridge provided to Malawian children aged 18-36 months with or without stunting when provided over 30 days compared to corn-soy blended flour porridge without added IAA will:

1. Increase gut digestive capacity

2. Increase plasma protein absorption

3. Reduce gut bacterial translocation

4. Reduce gut bacterial damage

5. Increase child weight

6. Increase plasma circulating amino acids

7. Increase gut microbial abundance and diversity

8. Increase fat free mass index and fat free percentage

Trial Locations

Locations (1)

Kamuzu University of Health Sciences

🇲🇼

Blantyre, Malawi

Kamuzu University of Health Sciences
🇲🇼Blantyre, Malawi

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.